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abdominal aortic aneurysms, if it was both effective and
safe. Randomized trials in animals that spontaneously
develop aortic aneurysms have shown that propranolol
decreases aneurysm growth and risk of rupture.12-17 The
mechanism is believed to be an effect of propranolol on
both cardiac contractility and aortic tensile strength.12-14
Three non-randomized trials in humans found that the
growth rate of abdominal aortic aneurysms in patients
receiving a beta-blocker was less than that in patients not
receiving a beta-blocker.18-20 Because of the frequency of
aneurysms and the morbidity and mortality associated
with elective surgery, a randomized trial to determine
whether beta-blockers truly decrease the growth rate in
abdominal aortic aneurysms was undertaken. Propranolol
was chosen as the beta-blocker to study because most ani-
mal and human experience with beta-blockade for
aneurysms has been with propranolol.
METHODS
Study design. A multicenter, randomized, placebo-
controlled, double-blind trial was carried out in 14
Canadian centers. Ethics institutional review boards
approved the study in all participating hospitals. An inde-
pendent Data Safety Monitoring Board reviewed the con-
duct of the study and performed one pre-planned interim
analysis of efficacy and safety when 447 patients had been
randomized with a mean follow-up period of 13 months.
The Board did not suggest any changes in the conduct of
the study.
A ruptured abdominal aortic aneurysm is an impor-
tant cause of morbidity and mortality. Conventional treat-
ment consists of observing patients with a small,
asymptomatic abdominal aortic aneurysm with regular
ultrasound scanning until the aneurysm reaches a size at
which elective resection is seriously considered. The exact
size at which the risk of rupture outweighs the risk of
surgery is not clear. A recent randomized trial showed no
difference in mortality between patients who were
observed with ultrasound scanning every 3 to 6 months
until the aneurysm size was greater than 5.5 cm and
patients who underwent surgery earlier (mean size, 4.6
cm), although health perception and bodily pain (mea-
sured by means of the 36-item Short-form Health Survey
[SF-36]1,2) were slightly better in the group of patients
who underwent early surgery.3,4
Elective aneurysm resection has been associated with a
perioperative mortality rate of 3% to 6% in most popula-
tion-based studies.5-11 It is likely that patients and clini-
cians would use a medication to delay the growth rate of
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Purpose: Animal and human studies have suggested that beta-blockade may decrease the growth rate of aneurysms. We
investigated whether propranolol decreases the growth rate of small abdominal aortic aneurysms (AAAs).
Methods: We randomly assigned patients with an asymptomatic AAA between 3.0 and 5.0 cm to receive either a placebo
(n = 272) or propranolol (n = 276) in a double-blind fashion. Patients were observed for a mean of 2.5 years. The pri-
mary end point was the mean annual growth rate as determined by means of ultrasound scanning performed every 6
months. Secondary outcomes were death, surgery, withdrawal from study medication, and quality of life measured by
means of the Short-form Health Survey (SF-36). The main analyses were performed by means of intention to treat.
Results: The two groups were similar at baseline: 84% were men with a mean age of 69 years and a mean AAA size of
3.8 cm. Fewer patients in the placebo group stopped their study medication (26.8% vs 42.4%; P = .0002). The annual
growth rate was similar in the two groups (placebo, 0.26 cm/y vs propranolol 0.22 cm/y; P = .11). There was a trend
toward more elective surgery in the placebo group (26.5% vs 20.3%; P = .11), but there was no difference in death rate
(placebo, 9% vs propranolol, 12%; P = .36). Patients in the propranolol group had significantly poorer quality of life
scores in the physical functioning, physical role, and vitality dimensions of the SF-36.
Conclusion: Patients with AAAs do not tolerate propranolol well, and the drug did not significantly affect the growth
rate of small AAAs. (J Vasc Surg 2002;35:72-9.)
Eligible patients. Patients were eligible when they
had an asymptomatic abdominal aortic aneurysm with a
maximum infrarenal diameter as measured by means of
ultrasound scanning between 3.0 to 5.0 cm and no con-
traindications to propranolol. Some centers chose to enter
only patients with aneurysm sizes between 3.0 and 4.5 cm.
Exclusion criteria. Patients were excluded when 
they had contraindications to beta-blockers (eg, asthma,
bradycardia), when they had a clinical need for beta-block-
ers (eg, post–myocardial infarction), when they had an
aneurysm that was known to have grown less than 0.2 cm
during the last year, when they were unlikely to be com-
pliant with the medication or follow-up, or when they 
had declined to participate in the study. Reasons for exclu-
sion were recorded on a checklist; when there was more
than one exclusion criterion, only the first one on the list
was recorded.
Patient recruitment. Patients were recruited with a
variety of strategies that were adopted by each center to
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meet local circumstances. The more common sources of
potential patients were direct referrals from participating
surgeons, screening of ultrasound scanning clinics, and
advertising in the local media. We had insufficient funds to
perform ultrasound scanning on at-risk populations, such
as older male patients who smoked. A form was filled out
for each patient who was referred to the study to record
the reasons patients were not eligible.
Randomization. A randomization list was computer
generated and stratified by center and aneurysm size (<3.7
cm, ≥3.7 cm). Medications were packaged by the pharma-
ceutical company (Pharmascience, Montreal, Canada), and
labeled with a randomization number. Study personnel
used the next number in the particular stratum. Neither
patients nor study personnel were aware of the treatment
allocation before randomization or throughout the study.
Intervention. Propranolol and the placebo were pro-
vided as pills that were identical in appearance and taste.
Patients were started on 20 mg of the study drug twice a
Fig 1. Eligible and ineligible patients with asymptomatic aneurysms assessed.
day, and the dose was increased to 40 mg in 1 week, 80
mg in 2 weeks, and 120 mg in 4 weeks when the patient
was tolerating the medication well and the heart rate was
greater than 50 beats per minute. The target dose was 80
to 120 mg twice a day. However, when patients could not
tolerate that dose, they were given the largest dose of
study medication that they could tolerate.
As part of routine quality control, the study drug was
intermittently tested to ensure that the placebo and pro-
pranolol were correctly labeled. In December 1996, when
371 patients had been randomized, it was found that a
small number of pills in the second batch of the study drug
provided by the company had been mislabeled.
Recruitment into the trial was immediately stopped, and
all study drugs were tested. To the best of our knowledge,
only two patients received the wrong study medication,
one for 13 days and one for 5 months. Both patients were
placed back on the correct study drug. Neither the
patients nor investigators were unblinded to the treatment
allocation.
Assessment before randomization. Before random-
ization, a history and physical examination were per-
formed. The latter concentrated on the blood pressure,
heart rate, wheezes or crackles on auscultation of the
lungs, and the presence of carotid, abdominal, or femoral
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bruits. An electrocardiogram was performed as a means of
ensuring that the patient did not have a heart block or any
other contraindication for propranolol. Patients also com-
pleted the SF-36 as a measure of health-related quality of
life. They were encouraged to complete it on their own,
but the study nurses clarified any questions.
Follow-up. Patients underwent ultrasound scanning
every 6 months, and more frequently when symptoms
developed. The ultrasound scans were performed in the
local hospital’s ultrasound scanning unit and, as much as
possible, an attempt was made to have the same ultra-
sonographer using the same machine examine the patient
each time. Before the start of the study, each center was
asked to have two individuals independently measure the
anteroposterior diameter of the aneurysm in 10 patients
who were not enrolled in the trial. Eighty percent of the
readings had a difference ≤0.2 cm. Study nurses saw the
patients 1 and 6 months after randomization and then
every 6 months thereafter. At these visits, patients com-
pleted the SF-36 and were asked questions about any hos-
pitalizations, symptoms attributable to their aneurysm, or
potential adverse effects of the study drug since they were
last seen. Their blood pressure and heart rate were also
measured. Patients who discontinued their study medica-
tion continued to be examined in the usual manner with
Table I. Patient characteristics
Placebo group (n = 272) Propranolol group (n = 276)
History
Mean age (years) 68.7 ± 7.6 69.1 ± 8.1
White 257 (94.5%) 265 (96.0%)
Male 233 (85.7%) 227 (82.3%)
Angina 33 (12.1%) 48 (17.4%)
CABS/PTCA 26 (9.6%) 28 (10.1%)
Carotid endarterectomy 7 (2.3%) 7 (2.5%)
Heart failure† 3 (1.1%) 8 (2.9%)
Claudication 48 (17.7%) 57 (20.7%)
Hyperlipidemia† 91 (33.5%)) 93 (33.7%)
Hypertension† 98 (36.0%) 98 (35.5%)
Impotence* 71 (30.5%) 67 (29.5%)
Myocardial infarction 45 (16.5%) 48 (17.4%)
Diabetes mellitus† 16 (5.9%) 18 (6.5%)
PV revascularization 16 (5.9%) 16 (5.8%)
Raynaud’s disease 6 (2.2%) 6 (2.2%)
Stroke 17 (6.3%) 17 (6.2%)
Transient ischemic attack 17 (6.3%) 17 (6.2%)
Current smoker 92 (33.8%) 98 (35.5%)
Physical examination
Wheezing 6 (2.2%) 10 (3.6%)
Crackles 16 (5.9%) 16 (5.8%)
Abdominal bruit 25 (9.3%) 22 (8.0%)
Systolic BP (mm Hg) 144 ± 19 147 ± 18
Diastolic BP (mm Hg) 82 ± 19 83 ± 10
Heart rate (beats/min) 72.8 ± 10.4 73.3 ± 11.0
Aortic size on ultrasound scanning
AP diameter (cm) 3.81 ± 0.48 3.81 ± 0.48
Transverse (cm) 3.94 ± 0.53 3.92 ± 0.54
*Impotence only assessed in men.
†Patients reported these disorders and were receiving pharmacological treatment for them.
CABS/PTCA, Coronary artery bypass grafting surgery/percutaneous transluminal coronary angioplasty; PV, peripheral vascular; BP, blood pressure; AP,
anteroposterior. 
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ultrasound scanning and to complete the SF-36. The
physicians of patients who refused follow-up were con-
tacted at the end of the study to determine whether the
patients had died, experienced a rupture of their
aneurysm, or undergone resection of the aneurysm.
Criteria for aneurysm resection. In centers in which
patients with an aneurysm between 3.0 and 4.5 cm were
randomized, surgeons participating in the trial agreed not
to perform surgery on patients without symptoms unless
the size of the aneurysm was greater than 5.0 cm. In cen-
ters in which patients with an aneurysm between 3.0 and
5.0 cm were randomized, surgeons agreed not to perform
surgery until the aneurysm was larger than 5.5 cm.
Patients with symptoms (eg, aneurysms that were tender
on palpation) could undergo surgery irrespective of
abdominal aortic aneurysm size.
Outcome measures. The primary outcome for effi-
cacy was the growth rate of the aneurysm, by using the
outer border of the anteroposterior diameter measured
with ultrasound scanning. Secondary outcomes included
growth rate by using the transverse diameter, mortality,
elective resection of aneurysms, reasons for permanent
withdrawal from study medication, and quality of life mea-
sured with the SF-36. An independent, external commit-
tee of three clinicians reviewed the deaths, without an
awareness of treatment allocation, and determined the
cause of death.
Sample size. The planned sample size of 600 patients
was made on the basis of an ability to detect a 25% relative
reduction in the aneurysm growth rate, assuming a
growth rate in the placebo group of 0.31 cm/y (SD, 0.44
cm/y) and a drop-out rate of 20%.
Analysis. The baseline characteristics were compared
descriptively. The primary analysis was performed on an
intention-to-treat basis (ie, all patients remained in their
initial allocation groups irrespective of subsequent failure
to stay on the allocated treatment). However, because the
question of whether propranolol can slow the growth of
an aneurysm in patients who can tolerate the drug is of
biological and clinical interest, a secondary analysis com-
pared patients who continued to take their study drug (ie,
an on-treatment analysis).
The primary outcome was the rate of change of the
anteroposterior diameter of the aneurysm, but secondary
analyses used the transverse diameter and the mean of the
two measurements. The analysis was restricted to study sub-
jects with at least two measurements 6 months after baseline.
The growth rate per year (slope) was calculated for each
study subject, and these rates were compared between the
two groups. A multivariate analysis of covariance was per-
formed, incorporating individual values of the covariates.
The proportion of patients in each group who perma-
nently withdrew from the study drug, who died, or who
had an aneurysm resected were compared by using the
chi-square analysis and survival analysis (Kaplan-Meier
curves were adjusted for the covariates of age, sex,
aneurysm size, and center with Cox regression analysis).
The changes in the eight dimensions and the physical and
mental component scores of the SF-36 in the two groups
were compared by using analysis of covariance.
RESULTS
Recruitment and follow-up. A total of 2141
patients with asymptomatic aneurysms between 3.0 and
5.0 cm were assessed for eligibility for the study. There
were 1589 patients who did not meet the eligibility crite-
Fig 2. A, Time to withdrawal of study drug. B, Time to surgery.




ria (Fig 1; they are listed in the order in which they
appeared on the data form, only 1 criterion per patient).
Thus, 552 patients were randomized. After randomiza-
tion, four patients were found to have been randomized in
error, three in the placebo group and one in the propra-
nolol group. Of these, two patients had an aneurysm size
measured with ultrasound scanning that was greater than
the eligibility criteria, and two other patients had thoracic
aneurysms. Because these patients clearly did not meet the
eligibility criteria for the study, they were not included in
the analysis. The 548 patients analyzed had a mean age of
69 years, 84% were men, and the mean size of the
aneurysm was 3.81 cm. The characteristics of the patients
in the two groups (propranolol and placebo) were similar
before randomization (Table I).
Eight patients were mistakenly randomized into the
wrong aneurysm-size stratum. They were included in the
analysis and were analyzed in the stratum according to
their actual aneurysm size. Twenty-seven patients refused
follow-up after randomization. However, at the end of the
study, we were able to determine whether all except six
had surgery or died. Of the 2431 follow-up ultrasound
scans required by the protocol, 1757 (72%) were per-
formed within 1 month of the scheduled time. Most of the
late ultrasound scans occurred because patients were out
of the country for their winter vacation.
The mean follow-up period was 2.5 ± 1.1 years (range,
0.0-4.5 years).
Discontinuation of study medication. The number
of patients who stopped their study medication before
surgery or the end of the study was 73 in the placebo
group (26.8%) and 117 in the propranolol group (42.4%;
difference, 15.6%; 95%CI, 7.6%-23.5%; P = .0002; Table
II; Fig 2A). Compared with patients in the placebo group,
patients in the propranolol group were more likely to stop
their study drug because of fatigue, shortness of
breath/bronchospasm, heart failure, and bradycardia.
When patients who stopped the medication because of the
need for beta-blockers were excluded, the number of
patients who withdrew because of adverse effects was 58
in the placebo group (21.3%) and 104 in the propranolol
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group (37.7%; difference, 16.4%; 95%CI, 8.7%-24.0%, P <
.0001). The mean daily dose of propranolol in patients
taking the drug was 130 mg at 6 months, 116 mg at 1
year, and 91 mg at 3 years. The mean heart rate in the
placebo group by using an intention-to-treat analysis was
74 ± 11 beats/min, versus 61 ± 11 beats/min in the pro-
pranolol group (P = .0001). The mean blood pressure was
also lower in the propranolol group, although the differ-
ence was not as marked (138/78 versus 140/80 mm Hg;
P = .22 for systolic blood pressure and .03 for diastolic
blood pressure).
Aneurysm surgery and death. More patients in the
placebo group underwent elective aneurysm resection
than patients in the propranolol group (72 [26.5%] vs 56
[20.3%]; difference, 6.2%; 95%CI, –0.1%-13.3%; P = .11;
Table III; Fig 2B). When only patients who continued tak-
ing their study drug were included, there were 55 resec-
tions in the placebo group and 35 resections in the
propranolol group (P = .02). The mean size of the
aneurysm on the last measurement before surgery was vir-
tually identical in the two groups (4.8 cm in the placebo
group, 4.7 cm in the propranolol group). Two patients in
the placebo group and one patient in the propranolol
group underwent surgery for a ruptured aneurysm. The
aneurysm size at the last ultrasound scanning measure-
ment before rupture was 5.1 cm in the patient receiving
propranolol and 5.7 and 4.3 cm in the two patients receiv-
ing the placebo. Twelve patients underwent aneurysm
resection at the time of another elective surgery, such as
aortofemoral bypass grafting. In the other patients, for
whom the primary reason for the surgery was elective
resection of the aneurysm, the last aneurysm size mea-
sured at a routine study visit before surgery was less than
4.5 cm in 35 patients, 4.5 to 5.0 cm in 49 patients, 5.1 to
5.5 cm in 27 patients, and 5.6 to 6.0 cm in 10 patients.
Twenty-six patients in the placebo group (9%) died
during the study, compared with 33 patients in the pro-
pranolol group (12%; P = .36; Table III; Fig 2C).
Table II. Reasons for permanently stopping study drug
early
Placebo group Propranolol group
(n = 272) (n = 276)
Fatigue 12 24
SOB/bronchospasm 6 16
Heart failure 2 7
Bradycardia/AVB 1 11
Impotence 2 1
Claudication/Raynaud’s disease 3 1
Need for beta-blocker 15 13
Patient choice 14 13
Other 18 31
Total 73 117
SOB, Shortness of breath; AVB, atrioventricular block.
Table III. Deaths and surgery
Placebo group Propranolol group
(n = 272) (n = 276)
Deaths
AAA rupture 1 1
Perioperative 1 1
Sudden death 6 6
Heart failure 0 3







*Other causes of death were: placebo group, pneumonia (2); propranolol
group, sepsis (2), head injury, aspiration, perforated ulcer, pneumonia,
unknown.
AAA, Abdominal aortic aneurysm.
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Aneurysm growth rate. The number of ultrasound
scanning measurements available with which to calculate
the growth rate were two measurements in 41 patients,
three measurements in 75 patients, four measurements in
82 patients, five measurements in 65 patients, six mea-
surements in 65 patients, seven measurements in 74
patients, eight measurements in 77 patients, nine mea-
surements in 40 patients, 10 measurements in 11 patients,
and 11 measurements in one patient. The growth rate by
using the anteroposterior diameter was 0.26 cm/y (SD,
0.31 cm/y) in the placebo group and 0.22 cm/y (SD,
0.28 cm/y) in the propranolol group (P = .11). The
results were similar when the transverse diameter was
used. Patients in the larger stratum had a more rapid
annual growth rate than patients in the smaller stratum
(0.24 cm/y vs 0.19 cm/y; P = .03). When patients were
only included while they were taking the study drug to
which they were assigned, the growth rate in the placebo
group was 0.26 cm/y (SD, 0.30 cm/y), versus 0.21 cm/y
(SD, 0.29 cm/y) in the propranolol group (P = .10). In a
post-hoc, exploratory subgroup analysis focusing on rapid
expanders, eight patients in the placebo group had a
growth rate of more than 0.75 cm/y, compared with one
patient in the propranolol group (P = .02).
Effect of covariates on outcomes. The effect of age,
sex, stratum, and center on death, surgery, and medication
withdrawal were evaluated. Older patients were more
likely to die than younger patients (relative risk [RR], 2.2
for patients ≥ 70 years; P = .004), but age had no impact
on the efficacy of propranolol. Older patients (RR, 1.55;
P = .02) and patients with aneurysms 3.7 cm or larger at
the time of randomization (RR, 4.2; P = .0001) were
more likely to have elective surgery than their comparison
groups. Adjusting for these covariates made the effect of
propranolol on elective surgery statistically significant (P =
.03). Women (RR, 1.20; P = .03) and patients in two of
the 14 centers were more likely to be withdrawn from
their study medication than their comparison groups, but
adjusting for these effects had no impact on the finding
that patients taking propranolol were much more likely to
be withdrawn from study medication than patients in the
placebo group.
Quality of life. The physical functioning, physical
role, and vitality dimensions of the SF-36 were significantly
worse in patients in the propranolol group (Table IV).
DISCUSSION
This study of 548 patients found no statistically signif-
icant effect of propranolol on the primary outcome of the
study—the mean growth rate of small abdominal aortic
aneurysms—even when only patients who tolerated their
study medication were analyzed. However, there was a
trend, which just became statistically significant when
adjustments were made for differences in covariates, for
patients receiving propranolol to be less likely to undergo
elective aneurysm resection. In a post-hoc analysis, there
were fewer patients with very rapid growth rates (≥ 0.75
cm/y) in the propranolol group. Thus, although the effect
of propranolol on the primary outcome was both statisti-
cally and clinically negative, secondary analyses raise the
possibility that propranolol may have had a small biologi-
cal effect. These results must be considered in light of
other studies and the adverse effects of propranolol.
Two other randomized trials have evaluated propran-
olol in patients with small abdominal aortic aneurysms.
Lindholt et al21 randomized 54 men with aneurysms
between 3.0 and 4.9 cm to receive 40 mg of propranolol
or a placebo twice daily and observed them for 2 years.
There was no difference in the mean annual growth rate
between the two groups in the intention-to-treat analysis
(0.28 cm in the placebo group vs 0.31 cm in the propran-
olol group) or in the on-treatment analysis. The frequency
of elective surgery was also unaffected by propranolol
(8.3% in the placebo group and 16.7% in the propranolol
group). Wilmink et al22 randomized 477 patients with
aneurysms between 3.0 and 4.5 cm to receive 40 mg of
propranolol or a placebo daily. In an abstract, they
reported that propranolol had no effect on the overall
mean annual growth rate (0.1 mm in the placebo group vs
0.06 mm in the propranolol group), but the growth rates
were extremely slow in both groups. However, the mean
annual growth rate in patients with aneurysms larger than
3.9 cm was lower in the propranolol group (0.43 mm in
the placebo group vs 0.13 mm in the propranolol group;
Table IV. SF-36
Baseline 1 month
Pl Pr P value Pl Pr P value
Pain 72.0 ± 23.8 70.2 ± 24.5 .38 74.3 ± 25.2 71.2 ± 25.2 .13
General health perceptions 71.3 ± 16.7 70.4 ± 17.8 .53 72.3 ± 16.1 69.8 ± 18.9 .12
Mental health 77.8 ± 17.9 78.9 ± 17.3 .45 78.3 ± 17.5 78.9 ± 17.6 .58
Physical functioning 74.1 ± 24.0 70.8 ± 23.9 .11 74.4 ± 23.8 68.9 ± 25.0 .006
Role—emotional 80.1 ± 34.3 79.5 ± 34.0 .84 82.8 ± 32.3 76.2 ± 36.6 .03
Role—physical 75.8 ± 36.9 70.0 ± 37.1 .07 75.4 ± 36.9 66.5 ± 40.6 .01
Social functioning 86.5 ± 20.3 85.0 ± 20.3 .55 87.2 ± 20.4 84.9 ± 21.1 .32
Vitality 65.0 ± 19.6 63.2 ± 20.1 .27 64.0 ± 19.8 57.6 ± 21.7 .002
P values are adjusted for differences at baseline. A higher score indicates a better quality of life
Pl, Placebo group; Pr, propranolol group.
P = 0.02), although it was extremely slow in both groups.
They did not report the frequency of surgery. Thus, none
of the three studies found a statistically significant effect of
propranolol on the mean aneurysm growth rate. Also, the
magnitude of the difference in growth rate between pro-
pranolol and placebo was small in all the studies, suggest-
ing that it is unlikely that a clinically important effect is
being missed because of inadequate sample size. The mean
follow-up period was less than 3 years in all three studies,
and patients with abdominal aortic aneurysms are usually
observed for life. However, given that an effect of propra-
nolol on growth rate was not seen within 2.5 years of fol-
low-up, it seems unlikely that it will become evident with
longer follow-up, especially because more patients will
stop their propranolol with time.
In our study, propranolol was poorly tolerated by
many patients. Thirty-nine percent of patients perma-
nently withdrew from propranolol because of adverse
effects, compared with 21% of patients taking the placebo.
The main reasons for the higher rate of withdrawal were
fatigue, shortness of breath, and bradycardia. At the time
of randomization, the patients had poorer quality of life
on all eight dimensions of the SF-36 than age-matched
men in the general Canadian population.2 After random-
ization, patients in the propranolol group had poorer
scores on the physical functioning, physical role, and vital-
ity dimensions of the SF-36 than patients in the placebo
group. Even more patients were unable to tolerate pro-
pranolol in the other two studies (60%21 and 69%22).
Thus, despite the possibility of a biological effect of pro-
pranolol suggested by some of the secondary analyses in
our study, the consistent lack of an effect on overall
growth rate in all three studies and the clear negative
impact of propranolol on quality of life suggest that pro-
pranolol should not routinely be used to slow the growth
of abdominal aortic aneurysms.
The limitations of our study should be considered.
During the study, routine testing of the study drug indi-
cated that some bottles of the study drug had been improp-
erly labeled. However, this was discovered when only a few
bottles had been opened, and to the best of our knowledge,
only a tiny fraction of patient follow-up was with patients
taking the wrong study drug. The dramatic difference in
mean heart rate, withdrawals because of adverse effects, and
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SF-36 scores attest to this. Despite regular feedback, some
surgeons operated on patients with no symptoms when the
aneurysm size was smaller than the protocol indicated.
However, this reflects what happens in actual clinical prac-
tice and would not have had an effect on the growth rates.
Because the study was double-blind, the decision to operate
was made without the knowledge of whether the patient
was taking propranolol. Ultrasound scanning, rather than
computed tomography scanning, was used as a means of
assessing the aneurysm growth rate. Although some inves-
tigations have suggested that computed tomography scan-
ning is more accurate, ultrasound scanning has demonstrated
good accuracy and is still used in many studies of aneurysm
growth rate. It is reasonable to wonder whether a “newer”
beta-blocker, such as metoprolol or atenolol, would have
been more effective. However, systematic overviews of the
efficacy of beta-blockers for myocardial infarction did not
find any difference in efficacy among the different types of
beta-blockers.23 It is unlikely that another beta-blocker
would be more efficacious than propranolol for patients
with abdominal aortic aneurysms. Finally, only approxi-
mately 25% of patients with aneurysms who were consid-
ered for this study were randomized. However, many
patients were not randomized because they had aneurysms
that were known to be growing slowly (there seemed to be
little point in exposing such patients to the potential adverse
effects of propranolol) or because they had a clear indica-
tion for, or contraindication to, propranolol. Thus, it is
likely that the patients in this trial were representative of
patients who would be considered for propranolol in the
real world.
In summary, in this randomized, double-blind trial,
there was no statistically or clinically significant effect of
propranolol on the growth rate of small abdominal aortic
aneurysms.
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APPENDIX. THE PROPRANOLOL ANEURYSMS
TRIAL (PAT) INVESTIGATORS.
Study centers (in order of patient recruitment).
(1) Ottawa Hospital, Civic Site: Dr G. Barber, Dr G.
Hajjar, Ms L. Hoey, Dr A. Laupacis, Dr N. MacPhail; (2)
London Health Sciences Centre, Victoria Campus,
London: Dr K. Harris, Ms M. Lovell, Dr W. G. Jameison,
Dr G. DeRose; (3) CHUQ, St. François d’Assise, Quebec
City: Dr Y. Douville, Ms M. Lortie, Dr R. Labbé, Dr H.
P. Noël, Dr C. Rouleau, Dr Y. M. Dion; (4) Sunnybrook
and Women’s College Health Sciences Centre,
Sunnybrook Campus, Toronto: Ms B. Bowyer, Dr D.
Kucey, Dr R. Maggisano; (5) Toronto Hospital, General
Division: Ms K. Clarke, Dr E. Etchells, Dr P. Kalman; (6)
Hamilton Health Sciences Corp., General Site: Dr J.
Nishikawa, Ms L. Taylor, Dr B. Doobay, Dr I. Doris; (7)
Jewish General Hospital, Montreal: Ms C. Doré, Dr
Miller, Dr Obrand; (8) Ottawa Hospital, General Site: Ms
S. Poloni, Dr G. Victor, Dr J. Wellington, Dr A. Hill; (9)
Montreal General Hospital and Royal Victoria Hospital:
Dr J. F. Morin, Ms L. Verreault, Dr O. Steinmetz; (10) St.
Joseph’s Health Center, London: Dr B. Larocque, Ms L.
Redford, Ms M. K. Scott; (11) St. Luc Hôpital, Montreal:
Ms S. Bisaillon, Dr P. Ghosn; (12) Wellesley Hospital,
Toronto, Dr F.M. Ameli, Ms L. Aro, Dr A. Lossing; (13)
Vancouver General Hospital and St. Paul’s Hospital,
Vancouver: Dr W. Cole, Dr Y. Hsiang, Dr B. Kassen, Ms
G. Kaulon; (14) Group Health Center, Sault Ste Marie:
Ms K. Barban, Dr S. Fratesi, Dr H. Lee, Ms S. McLean;
(15) CHRO, Hull: Ms P. Deschalet, Dr P. Nault; (16)
Victoria Hospital, Halifax: Ms L. Kraft, Dr B. O’Brien, Ms
H. Patil; (17) London Health Sciences Centre, University
Campus Site: Dr J. Mahon, Ms A. Powell.
Steering Committee. Dr Graeme Barber, Dr Gerry
Hill, Ms Lynda Hoey (study coordinator), Dr Andreas
Laupacis (principal investigator), Mr David Moher.
Data management and analysis. Ms Ann Gray (data
entry), Ms Emily Moens (data entry and management),
Ms My-Lihn Tran (data base manager), Ms Elizabeth
Yetisir (statistician).
Death Adjudication Committee. Dr Paul Hebert,
Dr Andrew Hill (Chair), Dr Carl vanWalraven.
External Safety and Efficacy Monitoring Com-
mittee. Dr David Ballard (Atlanta), Professor Michael
Gent (McMaster University, Hamilton; Chair), Dr Jeb
Hallett (Mayo Clinic, Rochester, Minn).
